Plandai Biotech Stock Performance
| PLPL Stock | USD 0.0002 0.0001 100.00% |
Plandai Biotech holds a performance score of 17 on a scale of zero to a hundred. The company holds a Beta of -7.06, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Plandai Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Plandai Biotech is expected to outperform it. Use Plandai Biotech standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to analyze future returns on Plandai Biotech.
Risk-Adjusted Performance
17 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Plandai Biotech are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating basic indicators, Plandai Biotech disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | 80.8 K |
Plandai |
Plandai Biotech Relative Risk vs. Return Landscape
If you would invest 0.01 in Plandai Biotech on September 3, 2024 and sell it today you would earn a total of 0.01 from holding Plandai Biotech or generate 100.0% return on investment over 90 days. Plandai Biotech is currently generating 10.4167% in daily expected returns and assumes 47.8368% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Plandai, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Plandai Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Plandai Biotech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Plandai Biotech, and traders can use it to determine the average amount a Plandai Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2178
| Best Portfolio | Best Equity | PLPL | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 47.84 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Plandai Biotech is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Plandai Biotech by adding it to a well-diversified portfolio.
Plandai Biotech Fundamentals Growth
Plandai Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Plandai Biotech, and Plandai Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Plandai Pink Sheet performance.
| Return On Asset | -0.21 | |||
| Operating Margin | (12.22) % | |||
| Current Valuation | 236.87 K | |||
| Shares Outstanding | 263.19 M | |||
| Price To Earning | (0.32) X | |||
| Price To Sales | 1.04 X | |||
| Revenue | 411.99 K | |||
| EBITDA | (2.1 M) | |||
| Cash And Equivalents | 7.96 K | |||
| Total Debt | 50.53 K | |||
| Debt To Equity | 0.95 % | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (1.1 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 6.82 M | |||
| Retained Earnings | (39.32 M) | |||
| Current Asset | 176 K | |||
| Current Liabilities | 15.44 M | |||
About Plandai Biotech Performance
By examining Plandai Biotech's fundamental ratios, stakeholders can obtain critical insights into Plandai Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Plandai Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Planda Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. Planda Biotechnology, Inc. is based in London, the United Kingdom. Diamond Ranch is traded on OTC Exchange in the United States.Things to note about Plandai Biotech performance evaluation
Checking the ongoing alerts about Plandai Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Plandai Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
- Analyzing Plandai Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Plandai Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Plandai Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Plandai Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Plandai Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Plandai Biotech's pink sheet. These opinions can provide insight into Plandai Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.